Suppr超能文献

遗传性血栓形成倾向与妊娠:产科视角

Inherited thrombophilia and pregnancy: the obstetric perspective.

作者信息

Bonnar J, Green R, Norris L

机构信息

Trinity College Department of Obstetrics and Gynaecology, St James's Hospital, Dublin, Ireland.

出版信息

Semin Thromb Hemost. 1998;24 Suppl 1:49-53.

PMID:9840692
Abstract

The identified main causes of inherited thrombophilia are deficiencies of antithrombin (AT), protein C, or protein S, resistance to activated protein C associated with Factor V Leiden mutation, mutant factor II, and inherited hyperhomocysteinemia. For women from symptomatic families, these defects may be associated with an increased risk of venous thrombosis during pregnancy and/or recurrent fetal loss. Inherited thrombophilia is common and appears to be a multigenic disorder. The thrombotic risk seems to be greatest for women who have AT deficiency or more than one thrombophilic defect. The abnormalities that are now recognized are only part of the genetic predisposition to thrombosis. When assessing thrombotic risk during pregnancy, acquired risk factors as well as genetic predisposition should be considered. Increasing age, obesity, immobility, and delivery by cesarean section are major acquired risk factors. Pregnancy should be planned as far as possible, and each patient should be managed individually. During pregnancy, heparin is the anticoagulant of choice, and treatment with warfarin should be avoided because of risks for the fetus. When patients receive long-term treatment with warfarin, pregnancy should be avoided or planned, and warfarin should be discontinued before conception or as soon as pregnancy is confirmed and before 6-weeks' gestation. For women who have AT deficiency, the incidence of thrombosis during pregnancy is between 20 and 40%. Adjusted-dose heparin throughout pregnancy is recommended, followed by warfarin for at least 3 months postpartum. For patients who have Factor V Leiden, mutant factor II, or a deficiency of protein C or protein S, treatment can be based on personal and family history. Thromboprophylaxis during late pregnancy and postpartum should be considered. Fetal loss may be increased for women with inherited thrombophilia. The risk appears to be greatest for women with AT deficiency and women with more than one thrombophilic defect. For women with recurrent fetal death and inherited thrombophilia, a number of case reports claim that prophylaxis with heparin during pregnancy has resulted in successful pregnancy.

摘要

已确定的遗传性血栓形成倾向的主要原因包括抗凝血酶(AT)、蛋白C或蛋白S缺乏,与因子V莱顿突变相关的活化蛋白C抵抗、突变的因子II以及遗传性高同型半胱氨酸血症。对于有症状家族史的女性,这些缺陷可能与孕期静脉血栓形成风险增加和/或反复流产有关。遗传性血栓形成倾向很常见,似乎是一种多基因疾病。对于患有抗凝血酶缺乏症或不止一种血栓形成倾向缺陷的女性,血栓形成风险似乎最大。目前公认的异常情况只是血栓形成遗传易感性的一部分。在评估孕期血栓形成风险时,应考虑获得性风险因素以及遗传易感性。年龄增长、肥胖、活动减少和剖宫产是主要的获得性风险因素。应尽可能计划妊娠,对每位患者应进行个体化管理。孕期肝素是首选抗凝剂,应避免使用华法林治疗,因为对胎儿有风险。当患者接受华法林长期治疗时,应避免妊娠或做好妊娠计划,在受孕前或确诊妊娠后且在妊娠6周前应停用华法林。对于患有抗凝血酶缺乏症的女性,孕期血栓形成的发生率在20%至40%之间。建议在整个孕期使用调整剂量的肝素,产后至少3个月使用华法林。对于患有因子V莱顿、突变因子II或蛋白C或蛋白S缺乏症的患者,治疗可基于个人和家族病史。应考虑在妊娠晚期和产后进行血栓预防。患有遗传性血栓形成倾向的女性流产风险可能会增加。对于患有抗凝血酶缺乏症的女性和患有不止一种血栓形成倾向缺陷的女性,风险似乎最大。对于有反复胎儿死亡和遗传性血栓形成倾向的女性,一些病例报告称孕期使用肝素预防已导致妊娠成功。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验